Patents Assigned to Ellipses Pharma Ltd.
  • AR+ breast cancer treatment methods
    Patent number: 11771682
    Abstract: A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 3, 2023
    Assignee: Ellipses Pharma Ltd.
    Inventors: Gary Hattersley, Jamal Saeh, Ziyang Yu, Chris Miller, Teeru Bihani